Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent advances in Canavan disease.

R Matalon1, K Michals-Matalon

  • 1University of Texas Medical Branch, Galveston, USA.

Advances in Pediatrics
|January 25, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids.

European journal of clinical nutrition·2017
Same author

Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids.

European journal of clinical nutrition·2016
Same author

Identification of a Novel 14q13.3 Deletion Involving the SLC25A21 Gene Associated with Familial Synpolydactyly.

Molecular syndromology·2015
Same author

Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine.

Journal of inherited metabolic disease·2007
Same author

Large neutral amino acids in the treatment of phenylketonuria (PKU).

Journal of inherited metabolic disease·2006
Same author

Abnormal expression of genes associated with development and inflammation in the heart of mouse maternal phenylketonuria offspring.

International journal of immunopathology and pharmacology·2005
Same journal

Two Steps Forward-One Step Back: Keeping Pace with Advances.

Advances in pediatrics·2025
Same journal

Pediatric Lymphadenopathy.

Advances in pediatrics·2025
Same journal

Vascular and Gastrointestinal Access in Children.

Advances in pediatrics·2025
Same journal

The Ouchless Pediatric Emergency Department.

Advances in pediatrics·2025
Same journal

Seizures and Shaking in Newborns and Babies.

Advances in pediatrics·2025
Same journal

Procalcitonin in Pediatric Emergency Medicine.

Advances in pediatrics·2025
See all related articles

Further research is essential to understand Canavan disease pathophysiology and how N-acetylaspartate (NAA) hydrolysis impacts brain degeneration. An animal model is crucial for advancing disease comprehension and developing gene therapies.

Area of Science:

  • Neuroscience
  • Genetics
  • Biochemistry

Background:

  • Canavan disease is a rare genetic disorder affecting brain white matter.
  • It results from a deficiency in aspartoacylase, an enzyme crucial for breaking down N-acetylaspartate (NAA).
  • The accumulation of NAA is implicated in the characteristic spongy degeneration of the brain.

Purpose of the Study:

  • To highlight the need for further investigation into the pathophysiology of Canavan disease.
  • To emphasize the role of NAA hydrolysis in the disease's neurological manifestations.
  • To advocate for the development of an animal model for Canavan disease research.

Main Methods:

  • This study is a review and theoretical discussion.
  • It synthesizes existing knowledge on Canavan disease.

Related Experiment Videos

  • It proposes future research directions.

    • Main Results:

    • The precise mechanisms linking impaired NAA hydrolysis to spongy degeneration remain unclear.
    • Current understanding necessitates further elucidation of Canavan disease pathophysiology.
    • An animal model is identified as a critical tool for future studies.

    Conclusions:

    • Elucidating the pathophysiology of Canavan disease requires more research.
    • Understanding the consequences of NAA hydrolysis deficiency is key.
    • Developing an animal model is vital for advancing therapeutic strategies, including gene therapy.